Press coverage about Omeros Corporation (NASDAQ:OMER) has been trending somewhat positive on Saturday, according to Accern. The research group scores the sentiment of media coverage by reviewing more than 20 million blog and news sources in real-time. Accern ranks coverage of public companies on a scale of -1 to 1, with scores closest to one being the most favorable. Omeros Corporation earned a news impact score of 0.22 on Accern’s scale. Accern also assigned news headlines about the biopharmaceutical company an impact score of 45.9489886775338 out of 100, indicating that recent media coverage is somewhat unlikely to have an impact on the stock’s share price in the next few days.
Here are some of the news headlines that may have impacted Accern Sentiment Analysis’s analysis:
- Omeros Corporation (OMER) Given Outperform Rating at Wedbush (americanbankingnews.com)
- Seattle’s third-largest biotech seeks $70 million in stock offering (bizjournals.com)
- OMEROS CORPORATION (NASDAQ:OMER) Files An 8-K Entry into a Material Definitive Agreement (4-traders.com)
- Omeros Corporation (OMER) noted a price change of -8.49% and Apollo Endosurgery, Inc. (APEN) closes with a move … – Stocks Gallery (stocksgallery.com)
- Omeros looks to raise $70M in stock offering to fuel drug development pipeline – GeekWire (geekwire.com)
Omeros Corporation (NASDAQ:OMER) traded down 2.00% during midday trading on Friday, hitting $22.03. The stock had a trading volume of 528,048 shares. The firm has a 50 day moving average price of $21.52 and a 200 day moving average price of $16.64. Omeros Corporation has a one year low of $7.20 and a one year high of $27.09. The stock’s market cap is $987.01 million.
Omeros Corporation (NASDAQ:OMER) last posted its quarterly earnings results on Tuesday, August 8th. The biopharmaceutical company reported ($0.23) earnings per share for the quarter, topping the Zacks’ consensus estimate of ($0.35) by $0.12. The company had revenue of $17.15 million during the quarter, compared to analyst estimates of $14.63 million. During the same period last year, the company posted ($0.32) earnings per share. The company’s revenue was up 71.5% compared to the same quarter last year. Equities analysts expect that Omeros Corporation will post ($1.40) EPS for the current year.
Several research firms recently weighed in on OMER. Zacks Investment Research downgraded Omeros Corporation from a “hold” rating to a “sell” rating in a research note on Friday, June 23rd. BidaskClub raised Omeros Corporation from a “hold” rating to a “buy” rating in a research note on Sunday, June 18th. Wedbush reaffirmed an “outperform” rating and issued a $47.00 price objective on shares of Omeros Corporation in a research note on Friday. Maxim Group reaffirmed a “buy” rating and issued a $24.00 price objective (up from $23.00) on shares of Omeros Corporation in a research note on Tuesday, August 8th. Finally, WBB Securities reissued a “strong-buy” rating and set a $75.00 price target on shares of Omeros Corporation in a research report on Wednesday, June 14th. One investment analyst has rated the stock with a sell rating, four have given a hold rating, five have given a buy rating and one has given a strong buy rating to the company. The stock currently has a consensus rating of “Buy” and a consensus price target of $32.80.
COPYRIGHT VIOLATION NOTICE: “Somewhat Favorable News Coverage Somewhat Unlikely to Affect Omeros Corporation (NASDAQ:OMER) Share Price” was first reported by Rincon Hill News and is the property of of Rincon Hill News. If you are reading this piece on another website, it was stolen and reposted in violation of U.S. & international copyright and trademark law. The correct version of this piece can be read at https://rinconhillneighbors.org/2017/08/19/omeros-corporation-nasdaqomer-getting-somewhat-favorable-press-coverage-report-finds-updated-updated.html.
In related news, VP Michael A. Jacobsen sold 24,000 shares of the company’s stock in a transaction on Thursday, June 15th. The shares were sold at an average price of $21.20, for a total value of $508,800.00. Following the completion of the sale, the vice president now directly owns 2,650 shares in the company, valued at $56,180. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. Also, VP Michael A. Jacobsen sold 12,000 shares of the company’s stock in a transaction on Friday, June 16th. The stock was sold at an average price of $24.95, for a total transaction of $299,400.00. Following the completion of the sale, the vice president now owns 19,500 shares of the company’s stock, valued at $486,525. The disclosure for this sale can be found here. Corporate insiders own 13.60% of the company’s stock.
Omeros Corporation Company Profile
Omeros Corporation is a biopharmaceutical company. The Company is engaged in discovering, developing and commercializing small-molecule and protein therapeutics for large-market, as well as orphan indications targeting inflammation, coagulopathies and disorders of the central nervous system. Its marketed drug product, Omidria (phenylephrine and ketorolac injection), is used during cataract surgery or intraocular lens (IOL) replacement.
Receive News & Ratings for Omeros Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Omeros Corporation and related companies with our FREE daily email newsletter.